β2受体激动剂联合孟鲁司特钠治疗支气管哮喘的临床效果及对患者肺功能、不良反应的影响分析

Analysis of the Clinical Effect ofβ2 Receptor Agonist Combined with Montelukast Sodium in the Treatment of Bron⁃chial Asthma and its Influence on Lung Function and Adverse Reactions

目的:研究采用β2受体激动剂联合孟鲁司特钠治疗支气管哮喘的临床效果及对患者肺功能指标及用药后不良反应发生率的影响,旨在为临床提供更多参考依据。方法:选取2020年1月—2021年4月禹州钧都医院收治的100例支气管哮喘患者作为研究对象,根据用药方案不同将其分为实验组和对照组,每组各50例。对照组给予孟鲁斯特纳治疗,实验组予以β2受体激动剂联合孟鲁司特钠治疗。观察两组患者治疗前、治疗后2 d、5 d、7 d的哮喘发作次数,对比其用药前后的肺功能指标[一秒用力呼气容积(FEV1)、FEV1/FVC、呼气峰值流量(PEFR)]变化情况,在所有患者治疗结束后对比其不良反应发生率及哮喘复发率。结果:实验组治疗后2 d、5 d、7 d的哮喘发作次数均低于对照组,差异有统计学意义(t=2.727、8.836、12.164,P<0.05);实验组用药后的PEFR、FEV1及FEV1/FVC等指标均优于对照组,差异有统计学意义(t=10.469、10.850、9.404,P<0.05);实验组治疗后哮喘症状复发率低于对照组,差异有统计学意义(χ2=4.421,P<0.05)。结论:β2受体激动剂联合孟鲁司特钠治疗支气管哮喘患者的疗效显著,在减少患者哮喘反复发作次数的同时,也可有效改善其肺功能相关指标,提高其治疗效果,且患者经二者联合治疗后病情复发率更低。但β2受体激动剂与孟鲁司特钠联合使用后可能会产生轻微不良反应,建议在临床实践中可结合患者情况酌情用药。

Objective:To study the clinical effect ofβ2 receptor agonist combined with montelukast sodium in the treatment of bronchial asthma and its influence on patients’lung function indexes and the incidence of adverse reactions after medication.Methods:100 patients with bronchial asthma admitted to the hospital from January 2020 to April 2021 were selected as study sub⁃jects,and they were divided into experimental group and control group according to different medication regimens,with 50 cases in each group.The control group was treated with montelukast,and the experimental group was treated withβ2 agonist combined with montelukast sodium.The number of asthma attacks before treatment,2 d,5 d and 7 d of treatment were observed in both groups,and the changes of their pulmonary function indexes(force expiratory volume in one second[FEV1],FEV1/FVC,peak expiratory flow rate[PEFR])were compared before and after drug administration.The incidence of adverse reactions and asthma recurrence rates were compared in all patients at the end of treatment.Results:The number of asthma attacks at 2 d,5 d and 7 d after treat⁃ment was lower in the experimental group than in the control group,with statistically significant differences(t=2.727,8.836,12.164,P<0.05).The PEFR,FEV1 and FEV1/FVC of the experimental group were better than those of the control group after drug administration,and the differences were statistically significant(t=10.469,10.850,9.404,P<0.05).The recurrence rate of asthma symptoms after treatment was lower in the experimental group than in the control group,and the difference was statistically signifi⁃cant(χ2=4.421,P<0.05).Conclusion:The efficacy ofβ2 agonist combined with montelukast sodium in the treatment of patients with bronchial asthma is remarkable.It can reduce the number of recurrent asthma attacks in patients while also effectively improving their lung function-related indexes and enhancing their therapeutic effects,and patients have a lower recurrence rate after the combination of the two.However,the combination ofβ2 agonists and montelukast sodium may cause minor adverse effects,and it is recommended that the drugs be used at the discretion of the patients in clinical practice.